Crumly & Associates Inc. Takes $85,000 Position in GT Biopharma, Inc. (OTCMKTS:GTBP)

Crumly & Associates Inc. acquired a new position in GT Biopharma, Inc. (OTCMKTS:GTBPGet Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 32,163 shares of the company’s stock, valued at approximately $85,000.

Other large investors have also modified their holdings of the company. Morgan Stanley increased its position in shares of GT Biopharma by 1,235.9% during the second quarter. Morgan Stanley now owns 34,840 shares of the company’s stock worth $540,000 after purchasing an additional 32,232 shares in the last quarter. Bank of America Corp DE purchased a new stake in GT Biopharma in the second quarter valued at $125,000. Invesco Ltd. purchased a new stake in shares of GT Biopharma during the 2nd quarter worth about $167,000. Welch Group LLC purchased a new stake in shares of GT Biopharma during the 3rd quarter worth about $67,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of GT Biopharma during the 3rd quarter worth about $64,000. 15.33% of the stock is owned by institutional investors.

A number of analysts have commented on the stock. B. Riley cut their price objective on shares of GT Biopharma from $26.00 to $18.00 in a report on Monday, January 24th. Zacks Investment Research cut shares of GT Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday, March 29th.

Shares of GT Biopharma stock traded down $0.15 during trading on Tuesday, hitting $2.39. 153,785 shares of the stock were exchanged, compared to its average volume of 158,846. The firm’s 50-day moving average price is $2.87 and its 200 day moving average price is $3.82. The stock has a market cap of $76.77 million, a price-to-earnings ratio of -0.90 and a beta of 0.41. GT Biopharma, Inc. has a 12-month low of $2.26 and a 12-month high of $19.73.

GT Biopharma (OTCMKTS:GTBPGet Rating) last posted its earnings results on Monday, March 28th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.31). On average, equities analysts forecast that GT Biopharma, Inc. will post -1.25 earnings per share for the current year.

GT Biopharma Company Profile (Get Rating)

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.

See Also

Want to see what other hedge funds are holding GTBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GT Biopharma, Inc. (OTCMKTS:GTBPGet Rating).

Institutional Ownership by Quarter for GT Biopharma (OTCMKTS:GTBP)

Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.